/PRNewswire/ Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to.
/PRNewswire/ Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it will.
– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors –– Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeutics expertise –ALAMEDA, Calif. & NEW HAVEN, Conn. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXE.
Exelixis (EXEL) and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.